Biomarkers in acute kidney injury (AKI)

Publication date: September 2017Source: Best Practice & Research Clinical Anaesthesiology, Volume 31, Issue 3Author(s): Su Hooi Teo, Zoltán Huba EndreAcute kidney injury is common in critically ill patients and portends a significant impact on mortality, progressive chronic kidney disease, and cardiovascular disease and mortality. Though most physicians alter therapy depending on changes in serum creatinine, this often represents delayed intervention. Various AKI biomarkers have been discovered and validated to improve timely detection, differentiation and stratification into risk groups for progressive renal decline, need for renal replacement therapy or death. This chapter will review AKI biomarkers validated over the past decade. We also describe the clinical performance of the biomarkers. We suggest that using AKI biomarkers to complement serum creatinine (or cystatin C) and urine output will better integrate patient care through earlier recognition and clinical outcome prediction after AKI.
Source: Best Practice and Research Clinical Anaesthesiology - Category: Anesthesiology Source Type: research